Latest filings (excl ownership)
6-K
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
26 Jun 24
6-K
Current report (foreign)
24 Jun 24
6-K
Current report (foreign)
18 Jun 24
6-K
Current report (foreign)
17 Jun 24
6-K
Current report (foreign)
7 Jun 24
6-K
Current report (foreign)
3 Jun 24
6-K
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
3 Jun 24
6-K
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 May 24
6-K
Current report (foreign)
24 May 24
6-K
Current report (foreign)
23 May 24
6-K
Evaxion Receives Nasdaq Notification
10 May 24
F-1
Registration statement (foreign)
6 May 24
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
17 Apr 24
6-K
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
2 Apr 24
6-K
Notice of Annual General Meeting
29 Mar 24
6-K
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
6-K
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Evaxion Announces Closing of $15 Million Public Offering
6 Feb 24
6-K
Securities Purchase Agreement
5 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
6-K
Evaxion Biotech Announces Pricing of $15 Million Public Offering
1 Feb 24
F-1/A
Registration statement (foreign) (amended)
31 Jan 24
F-1/A
Registration statement (foreign) (amended)
30 Jan 24
CORRESP
Correspondence with SEC
30 Jan 24
6-K
Current report (foreign)
26 Jan 24
6-K
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
24 Jan 24
6-K
Evaxion Announces Completion of ADS Ratio Change
22 Jan 24
UPLOAD
Letter from SEC
18 Jan 24
F-1
Registration statement (foreign)
12 Jan 24
6-K
Current report (foreign)
12 Jan 24
6-K
Notice of Extraordinary General Meeting
10 Jan 24
6-K
Evaxion Announces Plan to Implement ADS Ratio Change
8 Jan 24
6-K
Current report (foreign)
21 Dec 23
Latest ownership filings